title: Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.
abstract: BACKGROUND
  In randomised controlled trials, the frequency of treatment-emergent sexual dysfunction (TESD) in patients with major depressive disorder (MDD) at week 8 was lower with duloxetine than selective serotonin reuptake inhibitor (SSRI) therapy.
  
  
  METHODS
  This 6-month, prospective, observational study compared the frequency of TESD (using the Arizona Sexual Experience [ASEX] scale) in MDD patients treated with duloxetine or SSRI monotherapy in the first 8 weeks in normal clinical practice.
  
  
  RESULTS
  Physician-assessed TESD frequency at week 8 was comparable with duloxetine and SSRI monotherapy (23.9 and 26.2%, respectively; P = 0.545). Improvements in Clinical Global Impressions of Severity (CGI-S), 16-item Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR(16)), Integral Inventory for Depression (IID) total scores and remission rates were statistically significantly greater with duloxetine than SSRI monotherapy (P < 0.001, 0.010, <0.001, and 0.002, respectively), but TESD attenuated improvements in quality of life measures (EuroQoL questionnaire-5 dimensions [EQ-5D] and Sheehan Disability Scale [SDS] scores: ≤0.012). Several factors were significantly (P ≤ 0.05) associated with TESD at week 8 in this study.
  
  
  CONCLUSIONS
  TESD rates with duloxetine and SSRIs at week 8 were comparable, however, significant differences in effectiveness were observed in favour of duloxetine. Antidepressant tolerability with respect to TESD must be managed to maximize remission of depressed patients.
authors: ICR Medical, Eli Lilly de México, Mexico City, Mexico. duenas_hector@lilly.com
authors: Hector
authors: H
authors: Dueñas
authors: Arier
authors: A
authors: Lee
authors: Alan J M
authors: AJ
authors: Brnabic
authors: Ka-Fai
authors: KF
authors: Chung
authors: Chien-Han
authors: CH
authors: Lai
authors: Mohamed Gamal
authors: MG
authors: Badr
authors: Tiffany
authors: T
authors: Uy-Ponio
authors: Jorge Rodríguez
authors: JR
authors: Ruiz
authors: Padmaraju
authors: P
authors: Varrey
authors: Hu
authors: H
authors: Jian
authors: Martin
authors: M
authors: Dossenbach
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D000328:Adult; D003865:Major Depressive Disorder / Q000188:drug therapy*; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced*; D013876:Thiophenes / Q000009:adverse effects* / Q000494:pharmacology
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes